BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 10, 2015
 |  BioCentury  |  Finance

Venturing into diabetes

Why Metacrine's investors are funding a chronic disease company

While many VCs have deemed chronic diseases such as diabetes a no-fly zone because of clinical development costs, investors in Metacrine Inc.'s $36 million series A round are taking a contrarian approach. The expectation is the company's underlying science and management team with a track record of exits will justify the funding.

Metacrine has an exclusive license to two preclinical programs that originated in the lab of Ronald Evans, a nuclear hormone receptor expert who is an investigator at the Howard Hughes Medical Institute and director of the gene expression laboratory at the Salk Institute for Biological Studies.

One program is a protein-based insulin sensitizer for Type II...

Read the full 548 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >